If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Mass spectrometry === Multiple mass spectrometric techniques, including glow discharge mass spectrometry and direct analysis in real time mass spectrometry rely on Penning ionization. Glow discharge mass spectrometry is the direct determination of trace element in solid samples. It occurs with two ionization mechanisms: the direct electron impact ionization and Penning ionization. Processes inherent to the glow discharge, namely cathodic sputtering coupled with Penning ionization, yield an ion population from which semi-quantitative results can be directly obtained.
== Use and effects == According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, DMPEA is inactive in humans at doses of up to 1,000 mg orally and at a dose of 10 mg intravenously.
In β− decay, the weak interaction converts an atomic nucleus into a nucleus with atomic number increased by one, while emitting an electron (e−) and an electron antineutrino (νe). β− decay generally occurs in neutron-rich nuclei. The generic equation is:
Mister Donut has an orange and white logo in the likeness of a moustachioed chef. More recently, the chain developed a set of mascot characters based on its donuts. One character, "Pon de Lion" (ポン・デ・ライオン, Pon De Raion), a lion with a mane shaped like its "pon de ring" (ポン・デ・リング, Pon De Ringu) donut line, is used in Japan. In El Salvador, the mascots are five anthropomorphic doughnuts and a rooster that is used for the breakfast menu. The company uses the same logo as Japan, and the slogan is "La gran variedad" (The great variety).
Giving peanut products early in childhood may decrease the risk of allergies, and only breastfeeding during at least the first few months of life may decrease the risk of allergic dermatitis. There is little evidence that a mother's diet during pregnancy or breastfeeding affects the risk of allergies, although there has been some research to show that irregular cow's milk exposure might increase the risk of cow's milk allergy. There is some evidence that delayed introduction of certain foods is useful, and that early exposure to potential allergens may actually be protective. Following revisions to US and UK pediatric guidelines in 2015 and 2017 that encouraged introducing peanut products to high-risk infants at four to six months of age, one 2025 analysis found a 43% drop in the frequency of peanut allergies, with an estimated 40,000 cases prevented. According to that report, some pediatric experts have cautioned that real-world implementation of the guidelines may be inconsistent. Fish oil supplementation during pregnancy is associated with a lower risk of food sensitivities. Probiotic supplements during pregnancy or infancy may help to prevent atopic dermatitis.
Sources: en.wikipedia.org
123I is produced by proton irradiation of 124Xe. The caesium isotope produced is unstable and decays to 123I. The isotope is usually supplied as the iodide and hypoiodate in dilute sodium hydroxide solution, at high isotopic purity. 123I has also been produced at Oak Ridge National Laboratories by proton bombardment of 123Te. 123I decays by electron capture with a half-life of 13.22 hours. The emitted 159 keV gamma ray is used in single-photon emission computed tomography (SPECT). A 127 keV gamma ray is also emitted. 125I is frequently used in radioimmunoassays because of its relatively long half-life (59 days) and ability to be detected with high sensitivity by gamma counters. 129I is present in the environment as a result of the testing of nuclear weapons in the atmosphere. It was also produced in the Chernobyl and Fukushima disasters. 129I decays with a half-life of 15.7 million years, with low-energy beta and gamma emissions. It is not used as a tracer, though its presence in living organisms, including human beings, can be characterized by measurement of the gamma rays.
=== Fabrication of pure biomass based membrane === A biomass-based membrane is a membrane made from organic materials such as plant fibers. These membranes are often used in water filtration and wastewater treatment applications. The fabrication of a pure biomass-based membrane is a complex process that involves a number of steps. The first step is to create a slurry of the organic materials. This slurry is then cast onto a substrate, such as a glass or metal plate. The cast is then dried, and the resulting membrane is then subjected to a number of treatments, such as chemical or heat treatments, to improve its properties. One of the challenges in the fabrication of biomass-based membranes is to create a membrane with the desired properties.
He is a practising barrister and jurist and teaches course on human rights at Hebrew University of Jerusalem; author of best selling book on International Law (first published in 1977; 6th edition released in 2008); also edited Title to Territory, a collection of articles on title and sovereignty in international law. His textbook is one of the key tomes used in introductory courses on international law. Shaw has appeared before the European Court of Human Rights, European Court of Justice, the UK Supreme Court, and the International Court of Justice (ICJ). Before the ICJ, he has represented countries such as the UAE, Serbia, and Cameroon. He has represented Azerbaijan, Ukraine, Ireland, and Malaysia in front of the other courts. In January 2024, he was on the four-person team representing Israel in the case brought by South Africa in the ICJ regarding accusations of genocidal acts by Israel in Gaza in the course of the Gaza war.
Translational Research: The Journal of Laboratory and Clinical Medicine is a monthly peer-reviewed medical journal covering translational research. It was established in 1915 as The Journal of Laboratory and Clinical Medicine obtaining its current title in 2006. Jeffrey Laurence (Weill Cornell Medical College) has been editor-in-chief since 2006. He was preceded by Dale Hammerschmidt. It is the official journal of the Central Society for Clinical and Translational Research. It is published by Mosby.
Starting with the work of Carl Woese from 1977, genomics studies have placed the last universal common ancestor (LUCA) of all modern life-forms between Bacteria and a clade formed by Archaea and Eukaryota in the phylogenetic tree of life. It lived over 4.2 Gya. A minority of studies have placed the LUCA in Bacteria, proposing that Archaea and Eukaryota are evolutionarily derived from within Eubacteria; Thomas Cavalier-Smith suggested in 2006 that the phenotypically diverse bacterial phylum Chloroflexota contained the LUCA.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.